DAFTAR PUSTAKA

1. American Cancer Society (ACS) . Breast Cancer Facts and Figures 2017-2018. Atlanta; 2017.
2. WHO (2018) . Breast Cancer:Early Diagnosis and Screening.World Health Organization Western Pacific Region. https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/- Diakses Januari 2019
3. IARC (2018) . GLOBOCAN 2018 : Cancer Today. International Agency for Research on Cancer-WHO. http://gco.iarc.fr/today/home - Diakses Januari 2019.
4. IARC (2018). GLOBOCAN 2018 : Breast Fact Sheet. International Agency for Research on Cancer-WHO. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf - Diakses Januari 2019
5. Badan Penelitian dan Pengembangan Kesehatan. Laporan Riset Kesehatan Dasar (RISKESDAS) 2013. Jakarta: Kementrian Kesehatan RI; 2013.
6. Pusat Data dan Informasi Kemenkes RI. Infodatin Kanker 2015. Jakarta Selatan: Kementrian Kesehatan RI; 2015.
7. Pusat Data dan Informasi Kemenkes RI. Infodatin Bulan Peduli Kanker Payudara. Jakarta Selatan: Kementrian Kesehatan RI; 2016.
8. Badan Penelitian dan Pengembangan Kesehatan. Hasil Utama RISKESDAS 2018. Jakarta: Kementrian Kesehatan RI; 2018.
9. IARC (2018). GLOBOCAN 2018 : Indonesia Fact Sheets. International Agency for Research on Cancer -WHO. http://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf - Diakses Januari 2019.
10. Siegel RL, Miller KD, Jemal A. Cancer Statistics 2019. CA Cancer J Clin. 2019;69(1):7-34.
11. Kumar V, Cotran RS, Robbins SL. Neoplasma. In: Buku Ajar Patologi Robbins. 7th ed. Jakarta: EGC; 2012.p.185-237.
12. Lin DC, R.Genzen J. Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing. Breast Cancer Res Treat. 2018;167:269-76.
13. NCI (2013). Tumor Grade Fact Sheet. National Cancer Institute U.S Department of Health and Human Services. https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet - Diakses Januari 2019.
14. Skoog P, Ohlsson M, FernoÈ M, RydeÂn L, Borrebaeck CAK, Wingren C. Tumor tissue protein signatures reflect histological grade of breast cancer. PLoS One. 2017;12(6): e0179775.
15. Yao F, Zhang C, Du W, Liu C, Xu Y. Identification of Gene-Expression Signatures and Protein Markers for Breast Cancer Grading and Staging. PLoS One. 2015;10(9) : e013823.
16. Zheng K, Tan J-X, Li F, Yuan LI H, Zeng X-H, Ma BL. Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in

Western China: An Epidemiological Multicenter Study of 8619 Female Patients. Transl Oncol J Elsevier. 2018;11(4):1023-33.
17. Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, *et al*. A guide to systematic review and meta-analysis of prognostic factor studies. Br Med J. 2019;364: k4597.
18. Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci Elsevier. 2017:1-7.
19. Sandri MT, Salvatici M, Botteri E,Passerini R,Zorzino L,Rotmenz N, et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Res Treat. 2012;132(2):317-26.
20. Jing X, Liang H, Ha C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41:801-810
21. Rajabi H, Kufe D. MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. Biochim Biophys Acta Rev Cancer. 2017;1868(1):117-22.
22. Kufe DW. MUC1-C Oncoprotein as a Target in Breast Cancer; Activation of Signaling Pathways and Therapeutic Approaches. Oncogene. 2013;32(9):1073-81.
23. Serdarević N, Serdarević R, Memić A. Comparison of the performance of three cancer antigen (CA) 15-3 immunoassays. J Heal Sci. 2016;6(3):154-61.
24. NCI (2015). Tumor Markers Fact Sheet. National Cancer Institute U.S Department of Health and Human Services. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet - Diakses Januari 2019
25. Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum HER2 in combinationwith CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. 2015;440:16-22.
26. Shao Y, Sun X, He Y, Liu C, Liu H. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLoS One. 2015;10(7):e0133830
27. Choudhury CR, Neha A . A Study of Correlation of Pre-operative Serum CA-15.3 with Respect to Prognostic Factors and Early Recurrence in Breast Carcinoma in A Tertiary Care Centre in India. Int J Contemp Med Res. 2018;5(10).
28. Lee JS, Park S, Park JM, Cho JH, Kim SI. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol. 2012;24(5):1225-31.
29. Kemenkes RI (2015). Panduan Penatalaksanaan Kanker Payudara. Kementrian Kesehatan RI. http://kanker.kemkes.go.id/guidelines/ PPKPayudara.pdf - Diakses Januari 2019.
30. Cancer Council Australia. Understanding Breast Cancer. (Grove C, ed.).

Sydney; 2016.
31. Cancer Research UK (2017). Types of breast cancer and related conditions. https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-types-grades/types - Diakses Februari 2019
32. Sinn H-P, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care. 2013;8:149-54.
33. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis Elsevier. 2018;5:77-106.
34. Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y,et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017;13(11):1387-97.
35. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5(3):283-98.
36. Nindrea RD, Aryandono T, Lazuardi L. Breast Cancer Risk From Modifiable and Non-Modifiable Risk Factors among Women in Southeast Asia: A Meta-Analysis. Asian Pacific J Cancer Prev. 2017;18(12):3201-06.
37. Khalis M, Charbotel B, Chajès V, Rinaldi S, Moskal A, Biessy C, et al. Menstrual and reproductive factors and risk of breast cancer: A case-control study in the Fez region, Morocco. PLoS One. 2018;13(1):e0191333
38. Lambertini M, Santoro L, Mastro L Del, Nguyen B, Livraghi L, Ugolini D, et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treat Rev Elsevier. 2016;49:65-76.
39. Arthur R, Wang Y, Ye K, Glass A, Glinsberg M, Loudig O, et al. Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. Breast Cancer Res Treat. 2017;165:623–31.
40. Tan M-M, Ho W-K, Yoon S-Y, Mariapun S, Hasan SN, Lee DS-C, et al. A case-control study of breast cancer risk factors in 7,663 women in Malaysia. PLoS One. 2018;13(9):e0203469
41. Pizot C, Boniol M, Mullie P, Al E. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. Eur J Cancer. 2016;52:138-154.
42. Cathcart-Rake EJ, Ruddy KJ, Johnson RH. Modifiable Risk Factors for the Development of Breast Cancer in Young Women. Cancer J. 2018;24(6):275-84.
43. Cole L, Kramer PR. Human Cancers and Carcinogenesis. In: Human Physiology, Biochemistry and Basic Medicine. Boston: Elsevier; 2016.p.197-200.
44. Rasjidi I. Konsep Penyebab Kanker. In: Nugroho AW, editors. Buku Ajar

Onkologi Klinik. Jakarta: EGC; 2013.p.15-46.
45. Siddiqui IA, Sanna V, Ahmad N, Sechi M, Mukhtar H. Resveratrol nanoformulation for cancer prevention and therapy. Ann New York Acad Scienes. 2015;1348(Resveratrol and Health):20-31.
46. Joshi H, Press MF. Molecular Oncology of Breast Cancer. In: The Breast: Comprehensive Management of Benign and Malignant Diseases. 5th ed. Philadelphia: Elsevier; 2018.p.282-307.
47. Senkus E, Kyriade S, Ohno S, Zackrisson S. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26: v8-30.
48. Komite Penanggulangan Kanker Nasional. Pedoman Nasional Pelayanan Kedokteran Kanker Payudara. Jakarta : Kementrian Kesehatan RI; 2017.
49. Wöckel A, Festl J, Stüber T, Brust K, Stangl S, Heuschmann P. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG. Geburtshilfe Frauenheilkd. 2018;78(10):927-48.
50. ACS (2017). Breast Cancer Early Detection and Diagnosis. American Cancer Society. https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf -Diakses Februari 2019.
51. Rella R, Belli P, Giuliani M, et al. Automated Breast Ultrasonography (ABUS) in the Screening and Diagnostic Setting: Indications and Practical Use. Acad Radiol. 2018;25(11):1457-70.
52. Hill DA, Haas JS, Wellman R, Hubbard R, Lee C. Utilization of breast cancer screening with magnetic resonance imaging in community practice. J Gen Intern Med. 2018;33(3):275-83.
53. O'Connell A, Karellas A, Vedantham S, Kawakyu-O'Connor DT. Newer Technologies in Breast Cancer Imaging: Dedicated Cone-Beam Breast Computed Tomography. Semin Ultrasound, CT MRI. 2018;39(1):106-13.
54. Rakha EA, Ellis IO. Grading of Invasive Carcinoma. In: Shousha S, editor. Breast Pathology: Problematic Issues. Switzerland: Springer International Publishing; 2017.p.87-95.
55. International Agency for Research on Cancer. Introduction and general features. In: WHO Classification of Tumours of the Breast. ; 2012:13-32.
56. The American College of Surgeons. AJCC Cancer Staging Manual, 8th Edition. Chicago; 2018.
57. Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol. 2018;25:1783-85.
58. Knuttel FM, Menezes GLG, Diest PJ van, Witkamp AJ, Bosch M. A. A. J, van den Verkooijen HM. Meta-analysis of the concordance of histological grade of breast cancer between core needle biopsy and surgical excision specimen. Br J Surg. 2016;103(6):644-55.
59. Atanda AT, Imam MI, Umar AB, Yusuf I, Bello SS. Audit of Nottingham

System Grades Assigned to Breast Cancer Cases in a Teaching Hospital. Ann Trop Pathol. 2017;8(2):104-7.
60. Praça FSG, Marinho HS, Martins MBF, Gaspar R, Corvo ML, Medina WSG. Currrent aspects of breast cancer therapy and diagnosis basd on nanocarrier approach. In: Ficai A, Grumezescu AM, editors. Nanostructures for Cancer Therapy. Amsterdam: Elsevier; 2017.p.749-74.
61. Gupta SK, Kumar V, Anees A, Goel A. The study of prognostic significance of CA 15-3 in breast cancer. Int Surg J. 2018;5(2):580-83.
62. Li H, Chen K, Su F, Song E, Gong C. Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer. J Surg Res. 2014;189(1):48-56.
63. Vachani C (2018). Patient Guide to Tumor Markers. OncoLink. https://www.oncolink.org/cancer-treatment/procedures-diagnostic-tests/ blood-tests-tumor-diagnostic-tests/patient-guide-to-tumor-markers -Diakses Februari 2019.
64. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int. 2016:1-10.
65. Nath S, Mukherjee P. Muc1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20(6):332-42.
66. NCBI (2019) . MUC1: mucin 1, cell surface associated [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/4582. - Diakses April 2019.
67. Weizmann Institute of Science. MUC1 Gene. GeneCards Human Gene Database. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MUC1.- Diakses April 2019
68. Gupta AK, Khadke P. Co-expression and regulation of p53 and MUC1 in human carcinomas. Int J Curr Res. 2015;7(10):21127-32.
69. Rasyd L, Agus S, Asri A. Ekspresi p53 pada Karsinoma Payudara Duktal Invasif serta Hubungannya dengan Beberapa Parameter Patologik Prognosis. Maj Patol Indones. 2016;25(2).
70. Aman NA, Doukoure B, Koffi KD, Koui BS,Traore ZC, Kouyate M,et al. HER2 overexpression and correlation with other significant clinicopathologic parameters in ivorian breast cancer women. BMC Clin Pathol. 2019;19(1).
71. Siregar K. HER2 Overexpression in Relation to Breast Cancer Histopathological Grading: A Promising Prognostic and Predictive Biomarker for Breast Cancer. J Heal Med Nurs. 2015;21.
72. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014;4(64).
73. Garbar C, Mascaux C, Cure´ H, Armand B. MUC1/CD227 Immunohistochemistry in routine practice is a useful biomarker in breast cancer. J Immunoass Immunochem. 2013;34(3):232-45

74. C.White M, M.Holman D, E.Boehm J, A.Peipins L, MelissaGrossman, Henley J. Age and Cancer Risk: A Potentially Modifiable Relationship. Am J Prev Med. 2014;46(3):S7-15.
75. NCI (2012) Breast Cancer Risk in American Women. National Cancer Institute. U.S Department of Health and Human Service. https://www.cancer.gov/types/breast/risk-fact-sheet.- Diakses Juni 2019
76. Brenner DR, Brockton NT, Kotsopoulos JMC,Boucher BA, Courneya KS, Knight JA, et al. Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control. 2016;27:459-72.
77. Singh I, Singh J, Kaur R, Banipal RPS. A Comparitive Study of CA 15.3 Levels in Pre Treated Breast Cancer Patients and Controls. Int J Contemp Med Res. 2018;5(3):C1-4.
78. Imamura M, Morimoto T, Nomura T, Michishita S, Nishimukai A, Higuchi T, et al. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Oncol. 2018;16(26).
79. Apostolopoulos V, Stojanovska L, Gargosky SE. MUC1(CD227) : a multi-tasked molecule. Cell Mollecular Life Sci. 2015;72:4475-4500.
80. Alam M, Rajabi H, Ahmad R, Jin C, Kufe D. Targeting the MUC1-C oncoprotein inhibits self renewal capacity of breastcancer cells. Oncotarget. 2014;5(9):2622-34.
81. Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program. Arch Pathol Lab Med. 2014;138(8):1048-52.
82. Veta M, Diest PJ van, Willems SM,Wang H, Madabushi A, Cruz-Roa A, et al. Assessment of algorithms for mitosis detection in breast cancer histopathology images. Med Image Anal. 2015;20(1):237-48.
83. Fidalgo F, Rodrigues TC, Pinilla M, Silva AG, Maciel MdS, Rosenberg C, et al. Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. Tumor Biol. 2015;36:1835-48.
84. Wang M, Klevebring D, Lindberg J, Czene K, Grönberg H, Rantalainen M. Determining breast cancer histological grade from RNA-sequencing data. Breast Cancer Res. 2016;18(48).
85. Kyrochristos ID, Ziogas DE, Lykoudis EG, Roukos D. Breast cancer genome analysis in time and space: biomarker development strategy. Biomark Med. 2018;12(6):547-50.
86. Rafey M, Akhtar K, Rab AZ, Siddiqui SA. Serum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer.

Ann Woman Child Heal. 2017;3(4):A45-9.
87. Lal N, Irfan S, Zaidi N, Musa O, Mishra A, Rizvi I. Role of Biomarkers ALCAM and CA-15-3 in the Diagnosis of Breast Cancer: A Case - Control Study. Int J Contemp Med Res. 2017;4(8):1807-10.
88. Mudduwa LK, Wijayaratne GB, Peiris HH, Gunasekera SN, Abeysiriwardhana D, Liyanage N. Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis? Int J Womens Heal. 2018;10:329-35.
89. Ping Z, Xia Y, Shen T, Parekh V, Siegal GP, Eltoum IE, et al. A microscopic landscape of the invasive breast cancer genome. Sci Rep. 2016;6:27545.
90. Baird RD, Caldas C. Genetic heterogeneity in breast cancer: the road to personalized medicine? BMC Med. 2013;11(151).